Familial Hypercholesterolemia (FH)

Screening · §115

One in roughly three hundred people is born with a broken cholesterol-clearance system — LDL has been climbing inside their arteries since before they were born. Untreated, the typical first warning is a heart attack in the early forties for men or the early fifties for women, decades ahead of schedule. Treated with a generic pill from childhood, the same person lands at general-population risk. The catch: nine in ten carriers worldwide have never been diagnosed, so a family history of early heart disease or unusually high cholesterol does most of the detection work. If that family history is yours, get a lipid panel.

Test · Once Evidence Strong Chapter Screening

This is one of the rare conditions where a cheap generic pill, taken early enough, buys back decades of life. The work is in finding it. Most readers don't have it; the ones who do usually don't know yet. The flag is a close relative who had a heart attack young, or a cholesterol reading that runs in the family. Two minutes of family history can change a trajectory.

The LDL receptor is the gate the liver uses to pull cholesterol-carrying particles out of the bloodstream. In familial hypercholesterolemia (FH), one of those gates is broken from birth — most often a mutation in LDLR, with smaller shares in APOB (the dock on the LDL particle that the receptor latches onto) or gain-of-function PCSK9 (the protein that controls how fast receptors get recycled) Khera et al. 2016. The math is simple: half the clearance capacity means LDL piles up. People with one bad copy — heterozygous FH, about 1 in 311 worldwide — run untreated LDL-C of 190 to 450 mg/dL from birth Beheshti et al. 2020. People with two bad copies — homozygous FH, about 1 in 300,000 — run 400 to over 1,000 mg/dL, with the first heart attack landing in the teens or twenties.

What makes this different from ordinary high cholesterol is the time axis. Plaque grows in proportion to how long LDL particles have been crossing into your artery walls, not just how high your LDL is right now. By age thirty, an FH carrier has the cumulative LDL exposure of a typical sixty-year-old. By forty, a seventy-year-old. The math comes from a body of genetic-randomisation work: each 40 mg/dL of lifelong lower LDL cuts coronary disease risk by about 54% — roughly three times the per-unit benefit of starting a statin in midlife Ference 2012 Ference et al. 2017. FH front-loads the entire exposure; finding it early lets you reset the clock.

The story this disease tells

The dominant FH story is the dad who died of a heart attack at forty-eight, the mum who needed a stent at fifty-two, and the kids who grew up thinking it was just bad luck — or that "the cholesterol was always a bit high but the doctor said diet would handle it." Untreated heterozygous FH puts the first cardiac event in men at a median of about forty-two and in women at about fifty-two, against general-population medians in the mid-sixties and early seventies Nordestgaard et al. 2013. About half of untreated FH men have had a coronary event by fifty; roughly a third of untreated FH women by sixty.

The signs that occasionally tip off a careful doctor — yellow lipid deposits around the eyelids, a grey ring around the iris that shows up before forty-five (a corneal arcus), firm thickenings on the Achilles tendons (tendon xanthomata) — appear in maybe a third of carriers by their thirties. A careful physical exam catches them. Most carriers never get the exam. The first sign is the event.

The number that should make every reader pause is the cascade-screening number. FH is autosomal dominant: each first-degree relative of a confirmed carrier has a 50% chance of carrying it themselves. In national programmes where one identified case triggers systematic testing of parents, siblings, and children, the yield is roughly one in two relatives — the highest hit rate in clinical genetics Nordestgaard et al. 2013. For every undiagnosed family the disease passes through, three to eight people who could have started a statin in their twenties are heading toward a forty-something heart attack instead.

What treating it actually does

The clinical question — does early treatment prevent the events FH biology predicts? — was answered about as cleanly as preventive cardiology ever answers anything, by a twenty-year prospective follow-up of Dutch children put on statins as kids and tracked into their late thirties.

For carriers identified late — already in their thirties, forties, fifties — the playbook is the same and the maths still works, just with less margin. Adding ezetimibe on top of a high-intensity statin shaves another 15 to 20% off LDL. PCSK9 inhibitors (evolocumab, alirocumab) injected every two weeks knock off a further 55 to 60%, with hard outcome data from the FOURIER trial showing a 15% relative reduction in major cardiovascular events at two years on top of statin in high-risk patients Sabatine et al. 2017.

Homozygous FH — the rare and severe form, present from infancy — has its own answer in evinacumab, a monoclonal that targets a different LDL-clearance pathway entirely (ANGPTL3) and drops LDL by about half even in patients with essentially no working LDL receptors Raal et al. 2020 Cuchel et al. 2023. Twenty years ago that diagnosis was a death sentence by thirty. Today it is a complicated chronic condition.

When to suspect it, what to do

Two things should trigger an FH workup. The first is an untreated LDL number that no normal diet can explain: in adults, untreated LDL-C at or above 190 mg/dL (4.9 mmol/L); in children, at or above 160 mg/dL (4.1 mmol/L). The second is family history: a first-degree relative — parent, sibling, child — who had a heart attack or stroke before fifty-five in a man or sixty-five in a woman, or who is known to have FH, drops the threshold for suspicion considerably Nordestgaard et al. 2013.

Treatment is escalation rather than choice. Start with the highest-intensity statin tolerated (atorvastatin 40–80 mg or rosuvastatin 20–40 mg). If the LDL target — generally below 100 mg/dL for primary prevention, below 70 mg/dL if heart disease has already shown up — is not hit, add ezetimibe. If still short, add a PCSK9 monoclonal or twice-yearly inclisiran. For children with heterozygous FH, statin therapy is generally started between ages eight and ten Wiegman et al. 2015. For homozygous FH, treatment starts at diagnosis — often in infancy — and includes early PCSK9 inhibition, evinacumab, and sometimes lipoprotein apheresis Cuchel et al. 2023.

What this looks like in real life

The diagnostic workup is mostly insurance-covered. A fasting lipid panel is standard primary-care work. Commercial FH genetic panels run roughly $100 to $500 self-pay and are increasingly covered when clinical criteria for probable or definite FH are documented. The standard referral is to a lipid clinic — in the US the National Lipid Association maintains a directory, in the UK that role is HEART UK, and the Family Heart Foundation runs cascade-screening support across multiple countries.

The cascade-screening conversation is the practicality nobody warns you about. Once you are diagnosed, you are the starting point of a family screening chain — parents, full siblings, children, and from each of them outward. The yield is high (about half of first-degree relatives per round), but the social work is real: you are calling the cousin you have not spoken to in five years to ask about their cholesterol. Most cascade programmes give you a written letter to hand to relatives that explains the inheritance and what to ask their own doctor for, which makes the conversation roughly fifteen times easier.

Treatment costs themselves are small. Generic statins are essentially free in most healthcare systems. Generic ezetimibe is cheap. PCSK9 monoclonals carry list prices around $5,000 to $6,000 a year in the US but are typically covered for documented FH with prior authorisation. Evinacumab and apheresis are expensive and reserved for the rare homozygous form.

What most people get wrong

"It's a lifestyle thing — diet and exercise will fix it." Not for FH. Even an aggressive Mediterranean-pattern diet plus regular exercise drops FH LDL by about 5 to 15%. A high-intensity statin drops it by 45 to 55%. The gap is too big to be bridged by behaviour, and the years lost waiting to find that out are years of LDL exposure piling up in the artery walls.

"My labs came back normal." Worth checking what "normal" meant. Many labs flag LDL at or above 130 mg/dL as elevated but don't escalate further. An untreated LDL-C of 190 mg/dL or higher, especially in someone under forty with a family history of early heart disease, is a textbook FH flag that often goes unspoken in a rushed visit.

"I'm fifty already — the damage is done." Less true than it sounds. Even late-start FH treatment delivers large absolute risk reductions over the next decade or two; atherosclerosis can partially regress under aggressive LDL lowering. The earlier the better, but later is still much better than never.

"FH means a guaranteed heart attack." Twenty years of follow-up on Dutch children with confirmed FH treated from ages eight to eighteen put their cardiovascular-event risk by age thirty-nine at about 1% — indistinguishable from their unaffected siblings Luirink et al. 2019. The inheritance is loaded; the treatment unloads it.

Pregnancy and other pauses

Routine ALT and AST blood tests catch the rare liver-enzyme rise. Significant drug interactions exist with some antifungals, certain antibiotics in the macrolide family, and a few calcium-channel blood-pressure pills — mention the statin whenever a new prescription comes up. Muscle aches happen and are usually dose-related and reversible; serious muscle breakdown is rare (around 1 in 10,000 patient-years) but warrants stopping and getting checked.

Adjacent things worth looking at

Lipoprotein(a), often written Lp(a), is a separate inherited cardiovascular risk factor that runs on a different gene. Its screening logic mirrors FH — once per lifetime, ideally young — and it is worth checking alongside any FH workup. ApoB is a refined measurement that counts the actual atherogenic particles and is increasingly used alongside LDL-C for cardiovascular risk assessment. Polygenic hypercholesterolemia — high LDL caused by many small-effect variants rather than one big one — is more common in adults than monogenic FH and follows a different management path.

Related in the handbook

Helps

— A statin is step one; if your LDL is still high, these are the next tools that finish the job.

Diagnosis

— An advanced lipid panel is often how familial hypercholesterolemia gets caught.
— An ApoB or detailed lipid panel is how the sky-high LDL of FH gets spotted and tracked.

— FH is one of the tier-1 variants a clinical genetic panel can confirm — and screen relatives for.
— A calcium score can show how much damage decades of high LDL have already done in someone with FH.

Substance and claimed effects

Familial hypercholesterolemia (FH) is an autosomal-dominant disorder of LDL clearance, caused in >90% of confirmed cases by loss-of-function variants in LDLR, with smaller contributions from APOB (defective ligand for the LDL receptor) and gain-of-function PCSK9 variants Khera et al. 2016. Heterozygotes (HeFH) carry one defective allele and present with untreated LDL-C typically 190–450 mg/dL from birth; homozygotes / compound heterozygotes (HoFH) carry two and present with LDL-C 400–1000+ mg/dL and atherosclerotic events in childhood or adolescence Cuchel et al. 2023. The defining feature is not adult LDL elevation but cumulative lifetime LDL-C exposure: untreated FH patients reach a coronary atherosclerotic burden in their 30s–40s that the general population reaches in their 60s–70s Nordestgaard et al. 2013. The entry covers, holistically: lifetime cumulative LDL burden, premature atherosclerotic cardiovascular disease (ASCVD), the cascade-screening logic (autosomal dominance means half of first-degree relatives carry it), and treatment-intensity escalation (statin → ezetimibe → PCSK9 inhibitor → evinacumab / lipoprotein apheresis for HoFH). Reader-action axis is identification: 90%+ of cases worldwide remain undiagnosed Nordestgaard et al. 2013, and the dominant editorial concern is closing that gap before the first event.

Evidence by addressing question

Mechanism

The LDL receptor (LDLR), expressed predominantly on hepatocytes, clears circulating LDL particles by receptor-mediated endocytosis. A loss-of-function LDLR mutation in one allele halves receptor density; the remaining capacity cannot keep up with apoB-100-bearing particle production, so plasma LDL accumulates. APOB mutations (canonically R3500Q) disrupt the ligand on the LDL particle itself, so receptors are present but cannot bind. Gain-of-function PCSK9 mutations accelerate LDL-receptor degradation, producing the same downstream phenotype Ference et al. 2017. In homozygous FH, residual receptor activity is <2–25% of normal; in receptor-negative (null/null) HoFH, LDL clearance is almost wholly dependent on receptor-independent pathways, which dominate the rationale for newer therapies that bypass LDLR (lomitapide, evinacumab) Cuchel et al. 2023.

The downstream mechanism is well-established: apoB-bearing particles cross the arterial endothelium, are retained by intimal proteoglycans, undergo oxidative modification, and trigger monocyte recruitment and foam-cell formation. Plaque accumulation is monotonic in LDL-particle-years of exposure — the Mendelian-randomization framing in Ference et al. 2012 demonstrates that a 1 mmol/L (~39 mg/dL) lower LDL-C from birth confers ~54% reduction in CHD risk, ~3× larger than the same delta achieved by a statin started in midlife. This dose-time relationship is why FH, which front-loads LDL exposure across the first three decades, produces the early-event phenotype.

Evidence

Prevalence: the meta-analysis of ~11 million subjects across general-population and clinical cohorts puts HeFH at ~1:311 globally (95% CI 1:250 to 1:397), with higher rates in founder populations (French Canadians, Lebanese Christians, Afrikaners ~1:67–1:100) Beheshti et al. 2020. HoFH is ~1:300,000 in unselected populations, higher in consanguineous regions. The untreated lifetime ASCVD risk for HeFH is 10–13× general-population baseline for premature events; in cohort data on people with FH variants whose LDL-C was only moderately elevated (130–189 mg/dL), CHD risk was still ~2× variant-negative individuals at matched LDL — indicating LDL-particle exposure begins much earlier in FH carriers than the adult lipid panel captures Khera et al. 2016.

Statin-treatment evidence is unusually strong for a disease this rare to study directly. The 20-year prospective Dutch pediatric cohort (n=214 FH children treated with statins from age 8–18, plus 95 unaffected sibling controls) showed cumulative incidence of cardiovascular events of 1% by age 39 in treated FH children versus 26% in their untreated parents at the same age (parental mortality 7%) Luirink et al. 2019. Mean carotid intima-media thickness progression in the treated FH cohort (0.0056 mm/year) was indistinguishable from unaffected siblings (0.0057 mm/year) — i.e., early statin therapy abolished the atherosclerosis-acceleration signal. Statin RCTs aggregated by USPSTF: 10 pediatric trials, n=1230, showed mean LDL-C reduction of 81–82 mg/dL vs placebo at up to 2 years, with no observed effect on growth or puberty USPSTF 2023.

Beyond statins: ezetimibe adds ~15–20% LDL reduction on top of high-intensity statin. PCSK9 monoclonals (evolocumab, alirocumab) reduce LDL-C by ~55–60% on top of statin in HeFH (RUTHERFORD-2, ODYSSEY-FH cohorts); FOURIER showed a 15% reduction in major adverse cardiovascular events at 26 months in high-risk patients with established ASCVD on top of statin Sabatine et al. 2017. For HoFH where LDLR function is near-absent, evinacumab (ANGPTL3-directed monoclonal) reduced LDL-C by 47% absolute (49 percentage points vs placebo) at 24 weeks regardless of background therapy including apheresis Raal et al. 2020; long-term extension shows persistence through 192+ weeks Cuchel et al. 2023.

Diagnostic-criteria evidence: Dutch Lipid Clinic Network (DLCN) scoring combines LDL-C, family history of premature CHD, family history of high cholesterol, physical signs (tendon xanthomata 6 pts, corneal arcus <45y 4 pts), and DNA results. Score >8 = definite FH, 6–8 = probable, 3–5 = possible. Simon Broome uses LDL-C cutoffs (adults >190 mg/dL / 4.9 mmol/L; children <16y >155 mg/dL / 4.0 mmol/L) plus tendon xanthomata OR genetic confirmation for "definite," LDL alone plus family history for "possible." The MEDPED criteria use age-stratified LDL-C cutoffs alone — pragmatic for population screening.

Stakes

Untreated HeFH: first MI in men at median age ~42, in women ~52 (vs ~64 / ~72 general population). About 50% of untreated HeFH men have a coronary event by age 50; 30% of women by 60. Untreated HoFH: first event in childhood or teens; without modern therapy, survival past 30 was historically uncommon. The undiagnosed-cascade-screening gap means that for every index FH patient identified, ~3–8 first-degree relatives carry the variant and are presumed-eligible for screening; in well-run national programs (Netherlands historically, Norway), cascade testing yields ~50% positivity per relative tested, the highest-yield genetic screening in clinical medicine Nordestgaard et al. 2013.

Protocol

Screening: any adult with untreated LDL-C ≥190 mg/dL (≥4.9 mmol/L), any child with untreated LDL-C ≥160 mg/dL (≥4.1 mmol/L), or anyone with a first-degree relative with premature CHD (men <55, women <65) or known FH should be evaluated for FH Nordestgaard et al. 2013. Universal pediatric lipid screening once between ages 9–11 and again 17–21 is recommended by the AAP/NHLBI 2011 Expert Panel and reaffirmed by the National Lipid Association; USPSTF 2023 concluded evidence was "insufficient" for universal screening — controversy at this margin remains USPSTF 2023. Genetic testing is the diagnostic gold standard and improves cascade yield, but absence of a detected variant does not exclude FH (functional variants are sometimes missed; clinical FH on phenotypic criteria is treated identically).

Treatment escalation in HeFH: lifestyle is the floor (Mediterranean-pattern diet, exercise) but delivers only ~5–15% LDL reduction — never sufficient alone in FH. High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) is first-line; expected LDL reduction 45–55%. Add ezetimibe (10 mg/day) for additional 15–20%. Add PCSK9 monoclonal (evolocumab 140 mg q2w SC or alirocumab 75–150 mg q2w SC) if LDL target not met; further 50–60% reduction. Bempedoic acid is an option for statin-intolerant patients. Inclisiran (siRNA against PCSK9) gives ~50% LDL reduction with twice-yearly dosing after loading. LDL-C targets: in HeFH without ASCVD, <100 mg/dL (2.6 mmol/L); with ASCVD or other high-risk features, <70 mg/dL (1.8 mmol/L); EAS targets are even tighter (<55 mg/dL for very-high-risk). Pediatric statin initiation is generally age 8–10 for HeFH; HoFH requires statin from diagnosis (often infancy) plus early PCSK9i and evinacumab, plus consideration of lipoprotein apheresis (typically weekly or biweekly) Wiegman et al. 2015 Cuchel et al. 2023.

Cascade screening protocol: once an index case is confirmed, first-degree relatives (parents, full siblings, children) are systematically offered lipid screening ± genetic testing for the index variant. Yield ~50% per relative under autosomal-dominant inheritance. Second-degree relatives are tested in chains extending from each newly identified case. National cascade programs (Netherlands ran the historic exemplar; Norway, the Netherlands, UK NICE-program-based screening) have identified FH-positive yield up to 8× as efficient per test as opportunistic screening.

Contraindications

Statins are contraindicated in pregnancy (Category X) and during breastfeeding; FH women of reproductive age require contraception or peri-conception statin discontinuation planning. Active hepatic disease is a relative contraindication; ALT/AST monitoring is standard. Statin myopathy is dose-dependent and reversible; rhabdomyolysis is rare (~1 in 10,000 patient-years). Drug-drug interactions with CYP3A4 substrates (e.g., some antifungals, macrolides, calcium-channel blockers) require attention. Lomitapide carries hepatic-steatosis and GI-adverse-effect risk requiring REMS-program monitoring in the US.

Misconceptions

"High cholesterol is a lifestyle problem" — FH LDL is essentially diet-independent; the residual diet/exercise contribution in FH is small (~5–15%) and cannot substitute for pharmacotherapy. "Normal cholesterol on labs" — FH-pattern LDL ≥190 mg/dL adult, ≥160 mg/dL pediatric is often flagged as elevated but rarely triggered as suspected FH; the family-history red flag is widely missed. "Started statin late, too late now" — atherosclerosis regression is achievable even in midlife FH, though residual cumulative-exposure risk persists. "FH means certain heart attack" — adequately treated FH approximates general-population risk in the Dutch 20-year follow-up; the prognosis hinges on identification age, not the variant per se.

Practicalities

Diagnosis costs: a standard fasting lipid panel is universally insurance-covered. Commercial FH genetic-panel testing (LDLR/APOB/PCSK9 + LDLRAP1 for recessive form) is widely available, $100–500 self-pay and increasingly insurance-covered when DLCN ≥6 or Simon Broome possible/probable. Treatment: generic statins are essentially free ($4–20/month at major US pharmacies, NHS-prescribed in UK). Ezetimibe is now generic. PCSK9 monoclonals are $5,000–6,000/year US list, typically covered for FH with prior authorization; biannual inclisiran similarly priced. Evinacumab is $450,000+/year US list; restricted to HoFH. Apheresis costs $50,000–100,000/year. Lipid specialists are the standard referral; the National Lipid Association (US), HEART UK, and Family Heart Foundation maintain specialist directories and patient-support networks.

Audience

FH is autosomal dominant with full penetrance for LDL elevation but variable expressivity for clinical events. Female FH carriers have ~10-year-later average age at first event vs males (the general-population sex gap is preserved), but lifetime risk if untreated is similar. Pediatric statin therapy has 20+ years of safety data with no observed effect on growth, puberty, or neurodevelopment Luirink et al. 2019. Pregnant FH women need active management with discontinuation/restart planning and bile-acid sequestrants if pharmacotherapy is needed during pregnancy (these are non-systemically-absorbed). Founder-population prevalence (French Canadians, Christian Lebanese, Afrikaners, Ashkenazi Jews) is elevated 3–5× and should lower screening threshold.

Failure-modes

The dominant failure mode is non-diagnosis: ~90% of FH patients worldwide are never identified Nordestgaard et al. 2013, often presenting only after an MI at 40–50. Among diagnosed patients, the failure modes are (a) target undershoot — only ~20% of pediatric FH patients reach LDL-C <100 mg/dL on statin monotherapy at typical doses Luirink et al. 2019, requiring add-on therapy that is often not prescribed; (b) statin discontinuation due to perceived intolerance (the nocebo-effect literature here is large); (c) cascade-screening dropoff — index-case identification does not consistently propagate to relatives, with reported uptake rates of 30–60% in well-run programs and far lower in opportunistic settings; (d) Lp(a) confounding — elevated Lp(a) coexists with FH-pattern LDL in some patients and inflates apparent LDL-C measurement; (e) misattribution of elevated LDL to diet, leading to indefinite "lifestyle trial" delay before pharmacotherapy.

Out-of-scope

Polygenic hypercholesterolemia (the more common cause of LDL-C 190–250 in adults without an FH variant) is a separate substance; lipoprotein(a) (Lp(a)) is a separate inherited cardiovascular risk factor whose screening logic mirrors FH cascade but whose biology is distinct; ApoB measurement as a refinement on LDL-C for general cardiovascular risk assessment overlaps editorially. Atherosclerosis itself, statin pharmacology in non-FH populations, and primary-prevention screening for the general population are adjacent but separately scoped.

The credibility range

Optimist case

FH is one of the few areas of preventive cardiology where the mechanistic, genetic, observational, and trial evidence all converge unambiguously. The Mendelian-randomization framework Ference et al. 2012 Ference et al. 2017 nails causality of LDL on ASCVD using lifelong genetic exposure. The 20-year Dutch pediatric statin study Luirink et al. 2019 is as close to a definitive clinical answer as preventive medicine produces: starting statin in childhood essentially abolishes the FH-attributable event signal and matches unaffected sibling trajectories on subclinical-atherosclerosis markers. Identification is the bottleneck — the science is settled. With cascade screening done well (yields are ~50% per first-degree relative tested, the highest in clinical genetics), the marginal returns to investment in detection infrastructure are enormous: each index case typically identifies 3–8 affected relatives.

Skeptic case

The skeptic case is narrow and does not contest the underlying biology. It concerns: (a) universal pediatric screening — the USPSTF 2023 "insufficient evidence" determination USPSTF 2023 reflects the absence of an RCT showing morbidity/mortality benefit from screening per se (as opposed to from treatment in those identified), and the cost-effectiveness of universal vs cascade-only screening remains contested; (b) very-low-LDL targets in low-risk young HeFH patients lack hard endpoint data — most RCT data come from secondary-prevention populations, so the <70 or <55 mg/dL targets in young primary-prevention FH carriers are extrapolation; (c) PCSK9 monoclonals and evinacumab carry pharmacoeconomic concerns that affect access; (d) the nocebo / statin-intolerance literature suggests prescribed adherence is meaningfully lower than per-protocol trial adherence, eroding real-world benefit.

Author's call

The biology, the cumulative-LDL framing, the magnitude of underdiagnosis, and the magnitude of treatment benefit are all unequivocal. The entry lands strongly on the optimist side: FH is real, common (1 in ~300), dramatic in untreated outcome, and treatable to near-normal-risk if identified early. Controversy is low (1/5) — restricted to the universal-pediatric-screening cost-effectiveness debate and tight LDL targets in low-risk young carriers, neither of which alters the core editorial message. Evidence is 5/5 — multiple landmark RCTs, decades of registry data, Mendelian-randomization causality, and uniform guideline endorsement across AHA/ACC, EAS, NICE, and the National Lipid Association.

Stakeholder and incentive map

Specialty lipid clinics and the National Lipid Association / EAS / HEART UK / Family Heart Foundation — push expanded screening and cascade programs; the genuine clinical case aligns with their professional/institutional interests.
Industry — PCSK9 monoclonal makers (Amgen, Regeneron/Sanofi), inclisiran (Novartis), evinacumab (Regeneron) — commercial incentive to expand FH detection (it expands prescriptions for high-margin biologics); this incentive aligns with patient benefit but should be acknowledged.
Primary-care physicians — system-level under-incentivized for FH detection; lipid screening fits awkwardly into time-constrained visits, and follow-through on the "LDL ≥190 + family history of early MI" pattern is patchy.
Payers — historically resistant to PCSK9i and evinacumab due to cost; coverage criteria typically require documented FH (DLCN ≥6 or genetic confirmation) plus statin failure or intolerance.
Patient advocacy — Family Heart Foundation (US), HEART UK, FH Australasia Network drive awareness and cascade-screening uptake.
Skeptic / counter-incentive — the broader "lifestyle medicine" camp sometimes implicitly minimizes monogenic etiologies; the diet-only-can-fix-cholesterol message is loudest in popular wellness contexts and is structurally wrong for FH.

Population variability

Penetrance: LDL elevation is fully penetrant in HeFH from birth; clinical CV event penetrance varies with sex, lifetime LDL trajectory, smoking, hypertension, and concurrent Lp(a) elevation. Founder populations have markedly higher prevalence: French Canadians ~1:81, Lebanese Christians ~1:85, Afrikaners ~1:100, Ashkenazi Jews elevated Beheshti et al. 2020. Sex: women show the general ~10-year lag in first event vs men; pregnancy planning is a specific concern. Pediatric: lipid-panel sensitivity in unselected children is reduced because LDL-C in untreated pediatric HeFH overlaps with non-FH children at the upper end of the distribution — the 95th-percentile-LDL cutoff used in simplified screening (~130 mg/dL in children) is necessarily looser than the adult ≥190 mg/dL gate Wiegman et al. 2015. Race/ethnicity: under-detection is greater in Black and Hispanic populations in the US, both because of lower healthcare access and because FH awareness has historically focused on European-ancestry populations Luirink et al. 2023.

Knowledge gaps

(1) The cost-effectiveness of universal pediatric lipid screening (one-time, at age 9–11) vs cascade-only screening, in modern healthcare-cost environments with affordable generic statins, remains contested — the AAP/NLA position diverges from USPSTF on the strength of indirect evidence. (2) The absolute benefit of LDL-C targets <55 mg/dL in low-risk young HeFH primary-prevention patients lacks dedicated RCT data (extrapolated from secondary-prevention cohorts). (3) Optimal age of statin initiation in HeFH children — practice varies between 8 and 10 years, with limited head-to-head data on initiation age effects on long-term outcomes. (4) The clinical role of genetic testing when phenotypic criteria are met but no variant is found ("clinical FH, mutation-negative") remains an open management question. (5) Lp(a) screening alongside FH evaluation is now widely recommended but the management implication of elevated Lp(a) in an FH carrier (beyond more aggressive LDL lowering) lacks dedicated trials. (6) Equity gaps in FH detection across non-European-ancestry populations and lower-income settings are large and only partially mapped Luirink et al. 2023.

Action choice. Set to test with cadence once because identification — not treatment — is the bottleneck for this entry: 90%+ of cases worldwide are undiagnosed, and the reader-facing decision the entry asks for is "get screened / get your family screened." Treatment, once diagnosed, is unambiguously do daily, but the entry's centre of gravity is the diagnostic gate. decide was rejected — there is no meaningful tradeoff at the screening step, and treatment escalation is clinician-led rather than reader-led.

Category. screening over medical for the same reason: the editorial work of the entry is detection, not the clinical pharmacology of statins (which would belong in a separate cardiovascular-medication entry).

Holistic scoring on a condition rather than an intervention. Scored the substance as "identifying + treating FH" rather than as the untreated condition. Untreated FH's effects would be hugely negative on longevity, energy after early MI, etc., but the dimension scores are positive-sense by design (per meta.md §5b), so the entry is scored as the win delivered when the substance is acted on. This is consistent with how screening entries elsewhere should be rated.

Zero scores on most dimensions. beauty_direct, beauty_cumulative, health_short_term, energy, focus, sleep, mood all zero — FH is silent until events, and being diagnosed-and-treated does not change daily felt experience. Longevity (5) carries the entry. Honest zeros earn the high longevity score its legibility.

USPSTF vs AAP/NLA disagreement on universal pediatric screening. Surfaced briefly in the protocol section and in the research dossier credibility range. Not surfaced in the article body as a debate because it does not change the reader's decision (everyone agrees screening is the right action when family history or LDL flags are present; the disagreement is about whether to also screen children with no flags). Editor judgement: highlighting the controversy would dilute the screening message.

Out-of-scope topics flagged for future entries:

Lp(a) — inherited cardiovascular risk factor; warrants its own screening entry with similar cascade logic.
ApoB measurement as a refinement on LDL-C for general cardiovascular risk.
Polygenic hypercholesterolemia — more common than monogenic FH in adults, distinct management.
Statin pharmacology and adherence in the general (non-FH) population.
Lipoprotein apheresis as a standalone procedure for HoFH and severe refractory cases.
Universal pediatric lipid screening as a public-health policy entry — the USPSTF/NLA debate is its own topic.

Contraindications. Pregnancy and breastfeeding flagged because statin therapy — the universal first-line treatment — is paused in both states. The diagnosis itself is not contraindicated in these life stages, but a reader looking at the rank card needs to see that the action's downstream treatment has a pregnancy-related pause.

Founder populations. Mentioned in research dossier (French Canadians, Lebanese Christians, Afrikaners, Ashkenazi Jews) but not surfaced in the article — it would add length without changing the reader's action, since the family-history flag already captures the relevant population signal for any individual reader.

Cite chosen vs. cite considered. Used Sabatine 2017 (FOURIER) for PCSK9i outcomes rather than the FH-specific RUTHERFORD-2 because FOURIER carries the hard endpoint data; the FH-specific lipid-lowering effect is referenced separately. Used Luirink 2019 as the headline statin-in-FH-children paper; Luirink 2023 (Lancet 48-country prevalence) is cited for the equity / global-detection gap.